Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Bateman (Cape Town, South Africa), J. Fitzgerald (Vancouver, Canada), H. Reddel (Sydney, Australia), P. Barnes (London, United Kingdom), J. Zheng (Guangzhou, China), R. Lamarca (Barcelona, Spain), M. Puu (Gothenburg, Sweden), S. Ivanov (Gothenburg, Sweden), H. Parikh (Gaithersburg, United States of America), V. Alagappan (Gaithersburg, United States of America), P. O'Byrne (Hamilton, Canada). Efficacy of as-needed budesonide/formoterol in mild asthma: pooled analysis of SYGMA 1 and 2. 2275

Member's Comments

No comment yet.

Related content which might interest you: Preventing asthma exacerbations with budesonide/formoterol maintenance + relief: a pooled analysis Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008 Efficacy and safety of the new beclomethasone dipropionate/formoterol combination (HFA MDI) vs. budesonide/formoterol (DPI) in moderate to severe persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 434s Year: 2006 Efficacy of long-term formoterol therapy vs as-needed salbutamol use in patients with moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 426s Year: 2001 Budesonide/formoterol single inhaler therapy (SiT) provides superior asthma control compared with fixed dose (FD) budesonide or budesonide/formoterol in patients with severe persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 509s Year: 2004 Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD: results from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Efficacy and safety of QVA149 compared with salmeterol/fluticasone combination (SFC) in Chinese patients with moderate-to-severe COPD: A subgroup analysis from the LANTERN study Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study Source: Eur Respir J 2016; 48: 1030-1039 Year: 2016 Patient-reported clinical control and peak-flow: Effects of 30 versus 6 month treatment with inhaled corticosteroids (ICS) with/without long-acting2-agonists (LABA) in moderately severe COPD Source: Annual Congress 2011 - Disease management in specific primary care populations Year: 2011 Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide - a cost-effectiveness analysis Source: Eur Respir J 2001; 18: Suppl. 33, 517s Year: 2001 Once-daily QVA149 improves dyspnoea and health status compared with tiotropium plus formoterol in patients without ICS use: A post-hoc analysis of the QUANTIFY study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Pharmacoeconomic analysis of beclomethasone/formoterol versus fluticasone/salmeterol in the treatment of moderate-severe asthma in Spain Source: Annual Congress 2008 - Impact of patient education on cost-effectiveness of treatment Year: 2008 Formoterol turbuhaler compared with salbutamol as reliever medication in asthma: an exploratory analysis of the RELIEF study in patients using formoterol as maintenance therapy Source: Eur Respir J 2002; 20: Suppl. 38, 44s Year: 2002 A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: The FLAME study Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Improved and maintained asthma control with once-daily budesonide/formoterol single inhaler therapy in mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001 Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥1 exacerbation in the previous year: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma Source: ERJ Open Res, 7 (3) 00306-2021; 10.1183/23120541.00306-2021 Year: 2021 Effect of aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) on exacerbations in moderate-to-severe COPD: Pooled analysis of two studies Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Benefits of tiotropium/olodaterol compared with tiotropium in patients with COPD receiving only LAMA at baseline: pooled analysis of 4 clinical trials Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019 Efficacy of a combination therapy with single inhaler budesonide/formoterol in the treatment of acute exacerbations of COPD (AECOPD) Source: Eur Respir J 2004; 24: Suppl. 48, 252s Year: 2004 Comparable effectiveness of budesonide/formoterol combination and fluticasone for the treatment of cough variant asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013